Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Novo Nordisk is looking into whether smaller doses of its Wegovy pill can still help people lose weight. A new clinical trial kicked off on August 12, and it’s already drawing attention across the pharmaceutical world. The study will follow…
Novo Nordisk has a new media partner. The drugmaker just named Omnicom as its agency of record for advertising, ending a six-year run with WPP that started back in 2020. The switch comes at a busy moment for the company.…
Novo Nordisk wants to bring an oral version of Wegovy to South Africa. The timing has a lot to do with logistics, not just medicine. The Danish drugmaker says the pill form of its weight-loss treatment could work especially well…
The rivalry between the two biggest names in weight loss medicine just moved into a federal courtroom. Novo Nordisk filed a lawsuit against Eli Lilly on July 21, 2026. The company filed it in the U.S. District Court for the…
Novo Nordisk’s oral diabetes pill, Rybelsus, is carving out its own space in the GLP-1 market. Unlike its injectable siblings, Ozempic and Wegovy, Rybelsus comes as a tablet. That single difference makes it appealing to people who simply don’t want…
Novo Nordisk’s new weight-loss pill is quickly moving ahead of Eli Lilly’s competitor, and experts say the reason is simple: doctors trust what they already know. Even though Eli Lilly launched its own pill, Foundayo, soon after Novo Nordisk introduced…
Novo Nordisk plans to bring its oral version of Wegovy to international markets later this year. This strategic move helps the company grow beyond the injectable drug market it currently leads. Digital health platforms will serve as the main way…
Novo Nordisk recently shared impressive sales results for its new weight loss pill. The drug brought in about 330 million dollars during the first quarter. These numbers far exceeded what most financial experts expected for the period. In fact, this…
The global GLP-1 obesity market is currently facing a period of massive pricing shifts. In view of this, Novo Nordisk will slash the list prices of its semaglutide portfolio by nearly 50%. To be precise, this decision will drive the…